Sign in

CIK 0001601830

  • Large accelerated filer

RECURSION PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464099738
Phone
+1 385-269-0203
Business address
41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Former names
Recursion Pharmaceuticals, LLC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$701,222
in 5 filings, $701K under 10b5-1 plans

Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-03-06 Gibson Christopher Chief Executive Officer Exercise or conversion +8,674 $11.40 $99K 1,144,843
2024-03-06 Gibson Christopher Chief Executive Officer Sale −36,319 $11.86 $431K 1,108,524
2024-03-06 Gibson Christopher Chief Executive Officer Conversion +4,000 4,000
2024-03-06 Gibson Christopher Chief Executive Officer Sale −4,000 $11.56 $46K 0
2024-03-06 Gibson Christopher Chief Executive Officer Conversion +20,000 20,000
2024-03-06 Gibson Christopher Chief Executive Officer Sale −20,000 $11.55 $231K 0
2024-03-06 Gibson Christopher Chief Executive Officer Conversion +1,000 1,000
2024-03-06 Gibson Christopher Chief Executive Officer Sale −1,000 $11.56 $12K 0
2024-03-06 Gibson Christopher Chief Executive Officer Exercise or conversion · Stock Option (Right to Buy) −31,250 312,500
2024-03-06 Gibson Christopher Chief Executive Officer Exercise or conversion · Stock Option (Right to Buy) −8,674 399,002
2024-03-06 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −10,000 6,461,496
2024-03-06 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −4,000 511,000
2024-03-06 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −20,000 388,000
2024-03-06 Gibson Christopher Chief Executive Officer Conversion · Class B Common Stock −1,000 117,875
2024-03-05 Borgeson Blake Director Sale 10b5-1 −20,054 $12.06 $242K 7,272,809
2024-02-22 Marriott Tina President and COO Exercise or conversion 10b5-1 +8,000 $1.06 $8K 647,982
2024-02-22 Marriott Tina President and COO Sale 10b5-1 −8,000 $14.90 $119K 639,982
2024-02-22 Marriott Tina President and COO Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −8,000 496,000
2024-02-20 Borgeson Blake Director Sale 10b5-1 −19,745 $12.31 $243K 7,293,172
2024-02-20 Borgeson Blake Director Sale 10b5-1 −309 $13.04 $4K 7,292,863

Page 23 of 41 · 805 trades